HMSA Commercial plans cover immunizations in accordance with the recommendations of the Advisory Committee on Immunization Practices (ACIP).
ACIP Recommendations
The Advisory Committee on Immunization Practices (ACIP) develops vaccine recommendations for children and adults. The recommendations include the age(s) when the vaccine should be given, the number of doses needed, the amount of time between doses, and precautions and contraindications.
All of the ACIP’s recommendations are posted on the Centers of Disease Control and Prevention (CDC) webpage at: https://www.cdc.gov/vaccines/hcp/acip-recs/.
COVID-19 Vaccine and Vaccine Administration codes.
For commercial members, as of 09/12/2023, COVID-19 vaccines will be commercially available and covered by HMSA. Coverage is limited to the administration codes, see COVID-19 Immunization Administration codes.
See Additional billing information.
| Vaccine Codes (Alphabetically ordered by Vaccine) | ||
|---|---|---|
| Code | Long Description | Vaccine |
| 90589 | Chikungunya virus vaccine, live attenuated, for intramuscular use | Chikungunya |
| 90593 | Chikungunya virus vaccine, recombinant, for intramuscular use | Chikungunya |
| 90625 | Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use | Cholera |
| 90683 | Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use | Respiratory Syncytial Virus (RSV) |
| 90690 | Typhoid vaccine, live, oral | Typhoid |
| 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanparticle, saponin-based adjuvant, 5 mcg/0.2 mL dosage, for intramuscular use | COVID-19 vaccine - Novavax |
| 91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | COVID-19 vaccine – Pfizer-BioNTech |
| 91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | |
| 91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use | |
| 91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use | COVID-19 - Moderna |
| 91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use | |
| 91323 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use | |
| 90584 | Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use | Dengue |
| 90587 | Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use | |
| 90696 | Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine, when administered to children 4 through 6 years of age, for intramuscular use | Diphtheria, Tetanus, Pertussis, Poliovirus (DTaP-IPV) |
| 90697 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine, for intramuscular use | Diphtheria, Tetanus, Pertussis, Poliovirus, Haemophilus Influenzae type B, and Hepatitis B (DTaP-IPV-Hib-HepB) |
| 90698 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, for intramuscular use | Diphtheria, Tetanus, Pertussis, Poliovirus, and Haemophilus influenzae type B (DTaP-IPV/Hib) |
| 90700 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use | Diphtheria, Tetanus, and Pertussis (DTaP) |
| 90702 | Diphtheria and tetanus toxoids adsorbed when administered to individuals younger than 7 years, for intramuscular use | Diphtheria and Tetanus (DT) |
| 90723 | Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine, for intramuscular use | Diphtheria, Tetanus, Pertussis , Hepatitis B, and Poliovirus (DTaP-HepB-IPV) |
| 90758 | Zaire ebolavirus vaccine, live, for intramuscular use | Ebolavirus |
| 90647 | Haemophilus influenzae type b vaccine, PRP-OMP conjugate, 3 dose schedule, for intramuscular use | Haemophilus influenzae type b (Hib) |
| 90648 | Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use | |
| 90632 | Hepatitis A vaccine (HepA), adult dosage, for intramuscular use | Hepatitis A |
| 90633 | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | |
| 90634 | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use | |
| 90636 | Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use | Hepatitis A and Hepatitis B |
| 90739 | Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use | Hepatitis B |
| 90740 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use | |
| 90743 | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use | |
| 90744 | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use | |
| 90746 | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use | |
| 90747 | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use | |
| 90759 | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use | |
| 90748 | Hepatitis B and Haemophilus influenzae type b vaccine, for intramuscular use | Hepatitis B and Haemophilus influenzae type b (Hib-HepB) |
| 90649 | Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use | Human Papillomavirus Virus |
| 90650 | Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use | |
| 90651 | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | |
| 90630 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use | Influenza |
| 90653 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use | |
| 90654 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use | |
| 90655 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use | |
| 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | |
| 90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use | |
| 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use | |
| 90660 | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use | |
| 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | |
| 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use | |
| 90672 | Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | |
| 90673 | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use | |
| 90674 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use | |
| 90682 | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use | |
| 90685 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL, for intramuscular use | |
| 90686 | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | |
| 90687 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use | |
| 90688 | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | |
| 90689 | Influenza virus vaccine, quadrivalent (IIV4), inactivated , adjuvanted, preservative, preservative free, 0.25 mL dosage, for intramuscular use | |
| 90694 | Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use | |
| Q2034 | Influenza virus vaccine, split virus, for intramuscular use (Agriflu) | |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA) | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL) | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLUVIRIN) | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone) | |
| 90738 | Japanese encephalitis virus vaccine, inactivated, for intramuscular use | Japanese Encephalitis |
| 90707 | Measles, mumps and rubella virus vaccine, live, for subcutaneous use | Measles, Mumps, Rubella (MMR) |
| 90710 | Measles, mumps, rubella, and varicella vaccine, live, for subcutaneous use | Measles, Mumps, Rubella and Varicella (MMRV) |
| 90623 | Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use | Meningococcal (MENACWY-TT MENB-FHBP) |
| 90624 | Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use | Meningococcal |
| 90619 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier, for intramuscular use | Meningococcal and Tetanus (MENACWY-TT) |
| 90620 | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B, 2 dose schedule, for intramuscular use | Meningococcal (MenB-4C) |
| 90621 | Meningococcal recombinant lipoprotein vaccine, serogroup B, 2 or 3 dose schedule, for intramuscular use | Meningococcal (MenB-FHbp) |
| 90644 | Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type B vaccine, 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use | Meningococcal and Haemophilus influenzae type B (Hib-MENCY) |
| 90733 | Meningococcal polysaccharide vaccine serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier or CRM197 carrier, for intramuscular use | Meningocococcal Polysaccharide (MPSV4) |
| 90734 | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier or CRM197 carrier (MenACWY-CRM), for intramuscular use | Meningococcal ACWY Pneumococcal conjugate (MENACWY-D) |
| 90670 | Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | Pneumococcal conjugate |
| 90671 | Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use | |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use | |
| 90684 | Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use | |
| 90732 | Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use | Pneumococcal polysaccharide (PPSV23) |
| 90713 | Poliovirus vaccine, inactivated, for subcutaneous or intramuscular use | Poliovirus (IPV) |
| 90380 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use | Respiratory Syncytial Virus (RSV) |
| 90381 | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use | |
| 90382 | Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use | |
| 90678 | Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use | |
| 90679 | Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use | |
| 90680 | Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use | Rotavirus (RV5) |
| 90681 | Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use | Rotavirus (RV1) |
| 90714 | Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use | Tetanus and diphtheria (Td) |
| 90715 | Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | Tetanus, Diphtheria, and Pertussis (Tdap) |
| 90626 | Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use | Tick-borne encephalitis |
| 90627 | Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use | |
| 90691 | Typhoid vaccine, Vi capsular polysaccharide, for intramuscular use | Typhoid (ViCPs) |
| 90716 | Varicella virus vaccine, live, for subcutaneous use | Varicella (VAR |
| 90717 | Yellow fever vaccine, live, for subcutaneous use | Yellow fever |
| 90736 | Zoster (shingles) vaccine, live, for subcutaneous injection | Zoster (HZV) |
| 90750 | Zoster (shingles) vaccine, recombinant, subunit, adjuvanted, for intramuscular use | |
| Vaccine Administration Codes | ||
|---|---|---|
| Code | Long Description | Used for |
| 90460 | Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 0 through 18 years; first or only component of each vaccine or toxoid administered |
| 90461 | Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) | 0 through 18 years; each additional vaccine or toxoid component administered |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 1 vaccine (single or combination vaccine/toxoid) |
| 90472 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | Each additional vaccine (single or combination vaccine/toxoid) |
| 90473 | Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid) | Administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid) |
| 90474 | Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) | Administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) |
| 90480 | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | Covid-19 Administration code (i.e. 91318, 91319, 91320, 91321, & 91322) |
| 96380 | Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional | Respiratory Syncytial Virus administration code (i.e. used with 90380 or 90381) |
| 96381 | Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection | |
| G0008 | Administration of influenza virus vaccine | |
| G0009 | Administration of pneumococcal vaccine | |
| G0010 | Administration of hepatitis B vaccine | |
The original monovalent vaccines’ emergency use authorization (EUA) has been rescinded and those vaccines are no longer recommended for use, effective November 1, 2023
| Deleted Codes as of November 1, 2023 | ||
|---|---|---|
| COVID-19 Vaccine Codes | COVID-19 Vaccine Administration Codes | Manufacturer |
| 91300 | 0001A (1st dose) 0002A (2nd dose) 0003A (3rd dose) 0004A (Booster) |
Pfizer, Inc |
| 91301 | 0011A (1st dose) 0012A (2nd dose) 0013A (3rd dose) |
Moderna, Inc |
| 91302 | 0021A (1st dose) 0022A (2nd dose) |
Astra Zeneca, Plc |
| 91303 | 0031A (1st dose) 0034A (2nd dose) |
Janssen |
| 91305 | 0051A (1st dose) 0052A (2nd dose) 0053A (3rd dose) 0054A (Booster) |
Pfizer, Inc |
| 91306 | 0064A (Booster) | Moderna, Inc |
| 91307 | 0071A (1st dose) 0072A (2nd dose) 0073A (3rd dose) 0074A (Booster) |
Pfizer, Inc |
| 91308 | 0081A (1st dose) 0082A (2nd dose) 0083A (3rd dose) |
Pfizer, Inc |
| 91309 | 0091A (1st dose) 0092A (2nd dose) 0093A (3rd dose) 0094A (Booster) |
Moderna, Inc |
| 91310 | 0104A (Booster) | Sanofi Pasteur |
| 91311 | 0111A (1st dose) 0112A (2nd dose) 0113A (3rd dose) |
Moderna, Inc |
| 91312 | 0121A (1st dose) 0124A (Additional dose) |
Pfizer, Inc |
| 91313 | 0134A (Additional dose) | Moderna, Inc |
| 91314 | 0141A (1st dose) 0142A (2nd dose) 0144A (Additional dose) |
Moderna, Inc |
| 91315 | 0151A (1st dose) 0154A (Additional dose) |
Pfizer, Inc |
| 91316 | 0164A (Additional dose) | Moderna, Inc |
| 91317 | 0171A (1st dose) 0172A (2nd dose) 0173A (3rd dose) 0174A (Additional dose) |
Pfizer, Inc |
| N/A | 0041A (1st dose) 0042A (2nd dose) 0044A (3rd dose) |
Novavax, Inc |
• Please be sure to use the most up-to-date industry-standard procedure, revenue, and diagnosis codes from the current CPT ®′′, HCPCS Level II, and ICD-10-CM manuals, as recommended by the American Medical Association (AMA), the Centers for Medicare & Medicaid Services (CMS), and the American Hospital Association.
♣Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently.
Claim Billing Examples• ♦
♦ CPT, diagnosis codes and ACIP recommendations are subject to change and are used as reference examples only.
EXAMPLE 1
ACIP Hepatitis B recommendation state “all adults requesting protection from HBV infection, without requiring them to acknowledge a specific factor” should be vaccinated.
Adult member presents to a physician office requesting the Hepatitis B vaccination. The adult member does not disclose a specific risk factor and is not required.
Diagnosis:
- Z23 - Encounter for immunization
Code:
- 90746 - Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
- 90471 – Immunization Administration
Modifier:
- No modifier necessary
EXAMPLE 2
ACIP Hepatitis A recommendation states “persons with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients” should be vaccinated.
Adult member presents to a physician office for Hepatitis A vaccine because the member is considered a high risk candidate due to End Stage Renal Disease.
Diagnosis:
- N18.6 - End stage renal disease
- Z99.2 - Dependence on renal dialysis
- Z23 - Encounter for immunization
Code:
- 90632 - Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
- Append modifier SK
- 90471 – Immunization Administration
Modifier:
- SK - Member of high risk population (use only with codes for immunization)
EXAMPLE 3
ACIP recommendation states, “pregnant people during 32 through 36 weeks gestation, using seasonal administration, to prevent RSV lower respiratory tract infection in infants” should be vaccinated. Member informs physician or other qualified healthcare professional provider that they are 33 weeks gestation.
Diagnosis:
- Z23 - Encounter for immunization
- Z3A.33 - 33 weeks gestation of pregnancy
Code:
- 90678 – Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use
- 90471 – Immunization Administration
Additional Billing Information• ♣ ♦
- Bill the procedure code(s) representing the vaccine/toxoid and the appropriate administration code (s) on the same claim.
- HMSA prefers that a provider bills administration codes on a single line with a count (# of units).
- HMSA does not pay for vaccines provided by the State.Vaccines provided by the state should append modifier SL (State supplied vaccine) on the vaccine claim line with a nominal bill charge of $0.00. Note: IF system is limited and a charge is required, bill charge at $0.01.
- We encourage billing the COVID -19 vaccine & vaccine administration separately from other services rendered in the same visit.
- During the public health emergency (PHE) period, COVID-19 vaccines are funded by the federal government. Therefore, you are not required to bill for the COVID-19 vaccines (CPT 91300, 91301, or 91303).
- According to Noridian, UB claims billed for COVID-19 vaccine administration shall be billed with revenue code 0771 (Preventive Care Services – Vaccine Administration). Using other revenue codes may result to bundling into a case rate.
- Report CPT codes 90460 and 90461 only when the physician or other qualified healthcare professional provides face-to-face counseling to the patient/family during the vaccine administration.
- Code 90460 is reported once for the first component of each vaccine or toxoid administered by any route.
- Code 90461 is additionally reported for the counseling associated with each additional component of any combination vaccine or toxoid.
- A component refers to all antigens in a vaccine that prevents disease(s) caused by one organism. Multivalent antigens or multiple serotypes of antigens against a single organism are considered a single component of vaccines. Combination vaccines are those vaccines that contain multiple vaccine components. Conjugates or adjuvants in vaccines are not considered parts of the vaccine as defined above. See the reference table below.
- For more related information about vaccine and administration, refer to Immunization Administration Billed with Other Services for more related information.
- According to ACIP, effective September 22, 2023, * Maternal RSV vaccine is recommended for pregnant people during 32 through 36 weeks of gestation. Be sure to indicate the appropriate diagnosis code for the weeks of gestation. (e.g. Z3A.32, Z3A.33, Z3A.34, Z3A.35, or Z3A.36). Refer to https://www.cdc.gov/vaccines/hcp/acip-recs/ for the latest ACIP recommendation.
Components of Common Pediatric Vaccines
| Vaccine | Number of Vaccine Components | Immunization Adminstration Codes(s) Reported |
|---|---|---|
| Haemophilus influenzae type b - Hib | 1 | 90460 |
| Human Papillomavirus Virus | 1 | 90460 |
| Influenza | 1 | 90460 |
| Meningococcal | 1 | 90460 |
| Pneumococcal | 1 | 90460 |
| Rotavirus | 1 | 90460 |
| Haemophilus influenzae type b / Hepatitis B - (HepB-Hib) | 2 | 90460, 90461 |
| Tetanus and Diphtheria (Td) | 2 | 90460, 90461 |
| Diphtheria, Tetanus and Pertussis (DTaP) | 3 | 90460, 90461 x 2 |
| Tetanus, Diphtheria, and Pertussis (Tdap) | 3 | 90460, 90461 x 2 |
| Haemophilus influenzae type b - Hib | 1 | 90460 |
| Diphtheria, Tetanus and Pertussis (DTaP) / Polio - (DTaP-IPV) | 4 | 90460, 90461 x 3 |
| Diphtheria, Tetanus and Pertussis (DTaP) / Polio / Haemophilus influenzae type - (DTaP-Hib) | 4 | 90460, 90461 x 3 |
| Measles, Mumps, Rubella and Varicella (MMRV) | 4 | 90460, 90461 x 3 |
| Diphtheria, Tetanus and Pertussis (DTaP) / Hepatitis B / Polio - (DTaP-HepB-IPV) | 5 | 90460, 90461 x 4 |
| Diphtheria, Tetanus and Pertussis (DTaP) / Polio / Haemophilus influenzae type b - (DTaP-IPV/Hib) | 5 | 90460, 90461 x 4 |
• Please be sure to use the most up-to-date industry-standard procedure, revenue, and diagnosis codes from the current CPT ®′′, HCPCS Level II, and ICD-10-CM manuals, as recommended by the American Medical Association (AMA), the Centers for Medicare & Medicaid Services (CMS), and the American Hospital Association.
♣ Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently.
♦CPT, diagnosis codes and ACIP recommendations are subject to change and are used as reference examples only.
Revision History
| Date | Nature of Revision |
|---|---|
| 08/03/2026 | Migrated to new platform. |